Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 1 268 GBX 1.28% Market Closed
Market Cap: £10.8B

Smith & Nephew PLC
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Smith & Nephew PLC
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
Stock-Based Compensation
$43m
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Stock-Based Compensation
$36.3m
CAGR 3-Years
-7%
CAGR 5-Years
1%
CAGR 10-Years
11%
EKF Diagnostics Holdings PLC
LSE:EKF
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Stock-Based Compensation
£1.2m
CAGR 3-Years
-22%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Inspiration Healthcare Group PLC
LSE:IHC
Stock-Based Compensation
£49k
CAGR 3-Years
-40%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
EMV Capital PLC
LSE:EMVC
Stock-Based Compensation
£43k
CAGR 3-Years
-40%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
No Stocks Found

Smith & Nephew PLC
Glance View

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 111.74 GBX
Overvaluation 12%
Intrinsic Value
Price GBX1 268

See Also

What is Smith & Nephew PLC's Stock-Based Compensation?
Stock-Based Compensation
43m USD

Based on the financial report for Dec 31, 2025, Smith & Nephew PLC's Stock-Based Compensation amounts to 43m USD.

What is Smith & Nephew PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
11%

Over the last year, the Stock-Based Compensation growth was 7%. The average annual Stock-Based Compensation growth rates for Smith & Nephew PLC have been 2% over the past three years , 11% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett